(Q34243993)

31 July 2017

title

Future treatment of patients with HCV cirrhosis (English)

1 reference

31 July 2017

Marc Bourlière

1

1 reference

31 July 2017

Asma Khaloun

2

1 reference

31 July 2017

Claire Wartelle-Bladou

3

1 reference

31 July 2017

Valérie Oules

4

1 reference

31 July 2017

Isabelle Portal

5

1 reference

31 July 2017

Souad Benali

6

1 reference

31 July 2017

Xavier Adhoute

7

1 reference

31 July 2017

Paul Castellani

8

1 reference

31 July 2017

publication date

1 February 2012

1 reference

31 July 2017

1 reference

31 July 2017

volume

32 Suppl 1

1 reference

31 July 2017

page(s)

113-119

1 reference

Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02702.X

Pegylated interferon-α2a plus ribavirin for chronic hepatitis C in a real-life setting: the Hepatys French cohort (2003-2007).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02702.X

A review of the treatment of chronic hepatitis C virus infection in cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02702.X

Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02702.X

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02702.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02702.X

Peginterferon alpha-2b plus ribavirin for treatment of chronic hepatitis C with severe fibrosis: a multicentre randomized controlled trial comparing two doses of peginterferon alpha-2b.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02702.X

Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02702.X

Predictive value of on-treatment response during full-dose antiviral therapy of patients with hepatitis C virus cirrhosis and portal hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02702.X

Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02702.X

Low virological response and high relapse rates in hepatitis C genotype 1 patients with advanced fibrosis despite adequate therapeutic dosing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02702.X

Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02702.X

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02702.X

Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02702.X

Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02702.X

Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02702.X

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02702.X

Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02702.X

Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02702.X

Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02702.X

Treatment of chronic hepatitis C virus infection with pegylated interferon and ribavirin in cirrhotic patients awaiting liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02702.X

PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02702.X

Sustained virological responses following standard anti-viral therapy in decompensated HCV-infected cirrhotic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02702.X

Safety, tolerability, and efficacy of pegylated-interferon alfa-2a plus ribavirin in HCV-related decompensated cirrhotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02702.X

Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: A retrospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02702.X

Boceprevir for untreated chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02702.X

Telaprevir for previously untreated chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02702.X

Boceprevir for previously treated chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02702.X

Telaprevir for retreatment of HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02702.X

Response-guided telaprevir combination treatment for hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02702.X

10.1111/J.1478-3231.2011.02702.X

21 January 2018

Identifiers

DOI

1 reference

31 July 2017

1 reference